Ascendis Pharma

FDA cites ‘deficiencies’ in Ascendis’ application for parathyroid drug, jeopardizing potential approval
FDA cites ‘deficiencies’ in Ascendis’ application for parathyroid drug, jeopardizing potential approval
Endpoints
Ascendis Pharma
hypoparathyroidism
FDA
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge
Investors Business Daily
Ascendis Pharma
Skytrofa
earnings
Flag link:
Pfizer stumbles close to finish line in growth hormone race, extending the lead of rival Ascendis
Pfizer stumbles close to finish line in growth hormone race, extending the lead of rival Ascendis
Fierce Biotech
Pfizer
growth hormone deficiency
FDA
Ascendis Pharma
Flag link:
Ascendis crosses FDA finish line with once-weekly growth hormone—but Pfizer is hot on its trail
Ascendis crosses FDA finish line with once-weekly growth hormone—but Pfizer is hot on its trail
Fierce Pharma
Ascendis Pharma
Skytrofa
growth hormone deficiency
FDA
Flag link:
The big approvals still on the cards for 2021
The big approvals still on the cards for 2021
EP Vantage
FDA
drug approvals
Argenx
Novartis
AstraZeneca
Astellas
UCB Pharma
Ascendis Pharma
ChemoCentryx
Axsome Therapeutics
Flag link:
Go or no go? Aducanumab’s day of reckoning
Go or no go? Aducanumab’s day of reckoning
EP Vantage
Biogen
FDA
aducanumab
Ascendis Pharma
Novo Nordisk
TransCon hGH
semaglutide
Flag link:
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
The window of opportunity opens wider for Ascendis
The window of opportunity opens wider for Ascendis
EP Vantage
Ascendis Pharma
Transcon PTH
hypoparathyroidism
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Merck
Keytruda
Melinta Therapeutics
Amag Pharmaceuticals
Palatin
Acer Therapeutics
Sanofi
Regeneron
Alexion
Pfizer
Roche
Navidea Biopharmaceuticals
Ascendis Pharma
Scholar Rock
Adaptive Biotechnologies
BridgeBio
IPOs
G Medical Innovations
Karuna
Morphic Therapeutics
Flag link: